Crescita Therapeutics Stock Today
| CTX Stock | CAD 0.47 0.02 4.08% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Crescita Therapeutics is selling at 0.47 as of the 24th of July 2025; that is 4.08 percent decrease since the beginning of the trading day. The stock's open price was 0.49. Crescita Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 25th of April 2025 and ending today, the 24th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases, and their symptoms in Canada, the United States, and internationally. The company has 18.94 M outstanding shares of which 463 shares are currently shorted by private and institutional investors with about 0.06 days to cover all short positions. More on Crescita Therapeutics
Moving against Crescita Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Crescita Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Crescita Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Crescita Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
Crescita Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Crescita Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsCrescita Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Crescita Therapeutics' financial leverage. It provides some insight into what part of Crescita Therapeutics' total assets is financed by creditors.
| |||||
Crescita Therapeutics (CTX) is traded on Toronto Exchange in Canada and employs 3 people. Crescita Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Crescita Therapeutics's market, we take the total number of its shares issued and multiply it by Crescita Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Crescita Therapeutics operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 18.94 M outstanding shares of which 463 shares are currently shorted by private and institutional investors with about 0.06 days to cover all short positions.
Crescita Therapeutics has accumulated about 9.27 M in cash with 2.73 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45.
Check Crescita Therapeutics Probability Of Bankruptcy
Ownership AllocationCrescita Therapeutics holds a total of 18.94 Million outstanding shares. Crescita Therapeutics shows 11.05 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Crescita Ownership Details
Crescita Therapeutics Risk Profiles
Although Crescita Therapeutics' alpha and beta are two of the key measurements used to evaluate Crescita Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
Crescita Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Crescita Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Other Information on Investing in Crescita Stock
Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.